The complementary variation of circulating CD4/CD8− double negative T cells relative to CD4+ and other immune factors may improve the reliability of lymphocyte evaluation and is expected to become a potential therapeutic target for melanoma.[33] Our study also found that CD4−CD8− Tcell is a risk factor for melanoma. This evidence concerns the gene CD4 and melanoma.